• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Logo
  • COVID-19 Resource Center
  • Categories
    • Feature
    • Cardiology trends
    • Cardiology research news
    • Conference coverage
    • Consensus reports & Position papers
    • Resources for Cardiology Professionals
    • COVID-19 Resource Center
  • Videos
  • Cardiology Best Practices

Cardiology Update

The latest trends and advancements made in cardiology research.

Thromboembolism in COVID-19 patients despite thromboprophylaxis

November 9, 2020

Reading Time: 2 minutes

Cardiovascular events are frequently seen in association with coronavirus disease-2019 (COVID-19), particularly thromboembolisms. Researchers from Brigham and Women’s Hospital in Massachusetts just published results from their multicentre, observational cohort study investigating thromboembolism in patients with COVID-19 (COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications [CORONA-VTE NET], ClinicalTrials.gov identifier NCT04535128). The team analyzed a retrospective cohort of 1,114 patients with COVID-19, with a primary outcome of arterial or venous thromboembolism over 30 days.

Researchers first analyzed all 1,114 patients as a total cohort and then subdivided it into three smaller cohorts by site of care. These mutually exclusive cohorts consisted of patients who were admitted to the intensive care unit (ICU), patients who were admitted to hospital but not the ICU, and patients who were not hospitalized (outpatients).

Adverse outcomes more likely in ICU patients, despite receiving thromboprophylaxis

In the cohort of hospitalized patients who were admitted to ICU (n=170), 152 (89.4%) received prophylactic anticoagulants. ICU patients were more likely to experience major arterial or venous thromboembolism events (15.9% vs. 0.7%), major adverse cardiovascular events (20.2% vs. 1.1%), and symptomatic venous thromboembolism (VTE) (11.5% vs. 0.1%) than the 18 who were not receiving thromboprophylaxis.

At 30 days from diagnosis, major arterial or venous thromboembolic events, major adverse cardiovascular events, and symptomatic VTE occurred in 35.3%, 45.9%, and 27.0% of patients in this cohort, respectively.

In the cohort of hospitalized patients who were not admitted to the ICU (n=229), 194 (84.7%) received prophylactic anticoagulants. These patients were more likely to experience major arterial or VTE events (1.4% vs. 0.1%), major adverse cardiovascular events (3.8% vs. 0.1%), and symptomatic VTE (1.4% vs. 0.0%) than the 35 who were not receiving thromboprophylaxis.

At 30 days from COVID-19 diagnosis, major arterial or VTE events, major adverse cardiovascular events, and symptomatic VTE occurred in 2.6%, 6.1%, and 2.2% of patients in this cohort, respectively. The outpatient cohort (n=715) rarely used thromboprophylaxis. This cohort had a low risk of major arterial or VTE events, major adverse cardiovascular events, and symptomatic VTE.

Better strategies needed to identify risk in COVID19 patients

The high rate of major arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic VTE despite thromboprophylaxis in patients with COVID-19 necessitates the creation of better strategies for risk identification and mitigation.

This study lacked a control group of patients who had similar illnesses and risk factors but not COVID-19. Therefore, the extent to which COVID-19 itself increases the risk of thromboembolic events is unknown.

For more cardiology research news, join Cardiology Update on Facebook, Twitter, LinkedIn or Instagram.

Get our free eBook, Cardiology Best Practices, for a comprehensive look at the top position papers, consensus reports and more cardiology news important for daily practice.

Author: Kelly Schoonderwoerd

References

Original Article: Piazza G, et. al. JACC 2020 Nov 3; 76(18): 2060-72.


Check Out Related Articles

  • COVID-19 and the HeartCOVID-19 and the Heart
  • Very late stent-related events may occur in 50% of patientsVery late stent-related events may occur in 50% of patients
  • Managing coronary artery disease: MRI vs FFRManaging coronary artery disease: MRI vs FFR

Primary Sidebar

Cardiology News Highlights

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Most featured

Statin therapy: clinical benefits and potential risks

Statin therapies prevent both primary and secondary cardiovascular disease.However, long term safety … Continue Reading about Statin therapy: clinical benefits and potential risks

Cardiology Conferences 2021

Top Cardiology Conferences 2021

With the COVID-19 worldwide pandemic, conferences and congresses planned for 2020 converted to … Continue Reading about Top Cardiology Conferences 2021

N of 1 Trial - Statin side effects

SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include … Continue Reading about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Footer

Cardiology Update

Providing up-to-date developments in the field of cardiology in a clear and concise manner. All articles are written by professional medical journalists and subsequently reviewed by our editorial board. Cardiology Update provides breaking news, that matter to healthcare professionals in the field of cardiology. Subscribe for free to keep up with cardiology news updated regularly.

Learn More About Us

Contact Us

Recent

  • Top Cardiology Conferences 2021
  • SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
  • Top 10 Highlights of AHA 2020 Congress
  • Thromboembolism in COVID-19 patients despite thromboprophylaxis
  • Top 10 highlights of TCT 2020 Congress

Search

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Terms & Conditions | Privacy | Disclaimer
© Clinicalinx B.V. All rights reserved. Postbus 2278, 1000 CG Amsterdam

We use cookies to provide the services and features offered on our website, and to improve our user experience. Learn more Ok
Privacy & Cookies Policy
Necessary Always Enabled